



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/00, C07K 14/705	A1	(11) International Publication Number: WO 99/19468 (43) International Publication Date: 22 April 1999 (22.04.99)
(21) International Application Number: PCT/US98/19852 (22) International Filing Date: 23 September 1998 (23.09.98) (30) Priority Data: 08/943,687 15 October 1997 (15.10.97) US (71) Applicant: AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US). (72) Inventors: SIMONET, Scott; 2293 Watertown Court, Thousand Oaks, CA 91360 (US). DUNSTAN, Colin; 887 Tupelo Wood Court, Newbury Park, CA 91320 (US). SAROSI, Ildiko; 587F N. Ventu Park Road #139, Newbury Park, CA 91320 (US). (74) Agents: ODRE, Steven, M. et al.; Amgen, Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>	
(54) Title: MAMMALS LACKING EXPRESSION OF OSTEOPROTEGERIN (57) Abstract Disclosed is a mammal in which expression of the gene encoding Osteoprotegerin is suppressd. Also disclosed is a nucleic acid construct useful in preparing such a mammal, and a cell line containing such construct.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

MAMMALS LACKING EXPRESSION OF OSTEOPROTEGERIN

BACKGROUND

5

Field of the Invention

This invention relates to a mammal in which production of the protein encoded by the endogenous
10 gene for osteoprotegerin (OPG) has been completely suppressed.

Description of Related Art

15 Osteoprotegerin (OPG) was recently cloned and characterized as a novel member of the TNFR family that is capable of increasing bone density (Simonet et al. Cell 89, 309-319 (1997) and PCT Application No. US96/20621). By blocking a terminal step in the
20 differentiation and/or activation of osteoclasts from their precursors, OPG is one of several factors with the ability to offset the tight coupling between bone resorption and formation. Administration of recombinant OPG to normal mice or ovariectomized rats
25 results in an increase in bone mass and a decrease in bone resorption. OPG is expressed in cartilage rudiments of developing mouse embryos indicating it may be a physiological regulator of the ossification process.

30 Overexpression of OPG in transgenic mice resulted in severe osteopetrosis associated with a decrease in osteoclast number and activity in metaphyseal trabecular bone (Simonet et al. supra). The phenotype of OPG transgenic mice differs markedly
35 from other murine models of osteopetrosis. Genetic mutants such as op/op mice (*csf-1*^{-/-}) (Yoshida et al.

- 2 -

Nature 345:442-444 (1990); Wiktor-Jedrzejczak et al. Proc. Natl. Acad. Sci. USA 87:4828-4832 (1990); Marks et al. J. Heredity 67:11-18 (1976); Wiktor-Jedrzejczak et al. J. Exp. Med. 156:1516-1527 (1982)), microphthalmic mice (mi/mi) (Ebi et al. Blood 75:1247-1251 (1990), Graves et al. J. Cell. Phys. 145:102-109 (1990); Silvers The coat colors of mice: A model for mammalian gene action and interaction. Springer-Verlag, New York, (1979), Isozaki et al. Am. J. Path. 145:827-836 (1994)), and c-src^{-/-} and c-fos^{-/-} mice (Soriano et al. Cell 64:693-702 (1991), Wang et al. Nature 360:741-745 (1992), Grigoriadis et al. Science 266:443-448 (1994), Johnson et al. Cell 71:577-586 (1992)) all exhibit osteopetrosis accompanied by impaired tooth eruption and retarded growth. The defects in these genetic mutants are generally associated with decreased bone resorption attributable to decreased osteoclast numbers or inactive osteoclasts (Yoshida et al. supra, Wiktor-Jedrzejczak et al., supra; Graves et al., supra; Grigoriadis et al., supra; Boyce et al. J. Clin. Invest. 90:1622-1627 (1992), Lowe et al. Proc. Natl. Acad. Sci. USA 90:4485-4489 (1993)). In general, the long bones of the characterized osteopetrotic mouse models are shortened in length and the mice exhibit modest facial and cranial abnormalities. Osteopetrosis in OPG transgenic founder animals was severe in high expressors, yet occurred without shortening of the long bones or impaired tooth eruption (Simonet et al., supra).

It has been established that pharmacological doses of OPG result in increased bone density. However, there is a need to understand the physiological role of OPG in the development and maintenance of bone mass and other metabolic processes. In particular, there is a need to determine whether OPG is a physiological regulator of bone mass, and whether

- 3 -

other factors can compensate to maintain normal bone mass in its absence. Further, an animal model in which bone density is decreased would be valuable for screening novel therapeutics for diseases of bone loss.

5 Accordingly, it is an object of this invention to provide a mammal in which the gene encoding OPG has been suppressed.

 This and other such objects will readily be apparent to one of ordinary skill in the art.

10

SUMMARY OF THE INVENTION

 The invention relates to a mammal in which
15 expression of the gene encoding OPG is suppressed. Also provided is a nucleic acid construct useful in preparing such a mammal, and a cell line containing such a construct.

 In one embodiment, the present invention
20 provides a mammal comprising the gene encoding OPG, wherein one allele of the gene has been disrupted. In another embodiment, this invention provides a mammal comprising the gene encoding OPG, wherein both alleles of the gene have been disrupted. In yet another
25 embodiment, this invention provides a mammal comprising a disrupted OPG mutation, wherein the disruption results in a null mutation of the gene encoding OPG.

 Preferably, the mammal is a non-human mammal. More preferably, the mammal is a rodent. Optionally,
30 the rodent is a mouse.

 In still another embodiment, this invention provides a nucleic acid molecule comprising an OPG knockout construct. Optionally, this construct may be inserted into an amplification and/or an expression
35 vector, and the vector may be useful for transforming a prokaryotic or eukaryotic cell, or an embryo.

- 4 -

In one additional embodiment, the present invention provides a murine RW4 embryonic stem cell line comprising an OPG knockout construct.

5 Suppression of OPG expression results in a phenotype of decreased bone density and increased bone resorption. The OPG knockout mammals described herein provide a method for screening compounds that modulate bone resorption, and may help identify drugs that treat bone diseases such as osteoporosis.

10

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts preparation of an OPG
15 knockout construct. Restriction sites are indicated as follows: "RI" is *EcoRI*; "X" is *XmnI*; "P" is *PstI*. Exons are indicated as black boxes, and introns as thin black lines. (A) depicts a fragment of the OPG native gene containing exons 2-5, part of intron 1 and introns
20 2-4. (B) depicts the knockout construct in which the thymidine kinase (MC1-TK) cassette and the neomycin (Neo) cassette have been ligated into the OPG gene. (C) Depicts the structure of the targeted allele following homologous recombination at the OPG locus. The small
25 open box represents the probe used to screen for recombinant ES cell clones.

Figure 2 depicts Southern blot analysis of *EcoRI* digested genomic DNA from wild type (+/+), or
30 targeted (+/-) ES cell clones. The wild type allele is a 1.7 kb *EcoRI* fragment, and the targeted allele is a 3.2 kb *EcoRI* fragment.

Figure 3 depicts Southern blot analysis of
35 *PstI* digested genomic DNA from wild type (+/+), heterozygous (+/-), and homozygous (-/-) OPG knockout

- 5 -

mice. The wild type allele is a 2.3 kb PstI fragment, and the targeted allele is a 3.0 kb PstI fragment.

Figure 4A depicts whole body x-ray of 2 month old wild type (+/+), heterozygous (+/-), and homozygous (-/-) OPG knockout mice.

Figure 4B depicts x-rays of the femurs of OPG -/-, +/+ and +/- mice. The strongest phenotype is seen in #1-38. The cortical bone is thinned, the growth plate is not visible. The +/- mice are not different from the +/+ mice.

Figure 5 depicts bone morphology in OPG -/- (#38) versus normal control (#45) mouse. A - normal control humerus (#45), H & E, size bar 500 microns, note normal morphology; B - OPG -/- humerus (#38), H & E, size bar 500 microns, note severe osteoporosis and mechanical damage of the articular surface; C - normal control vertebra (#45), H & E, size bar 500 microns, note normal morphology; D - OPG -/- vertebra (#38), H & E, size bar 500 microns, note severe osteoporosis and degenerative damage of the intervertebral disk; E - normal control humerus (#45), H & E, size bar 100 microns, note normal morphology; F - OPG -/- humerus (#38), H & E, size bar 100 microns, note severe osteoporosis, increased porosity in the cortical bone; G - normal control vertebra (#45), TRAP stain, size bar 25 microns, note normal number of osteoclasts (arrow); H - OPG -/- vertebra (#38), TRAP stain, size bar 25 microns, note slightly increased number of osteoclasts (arrows).

35

DETAILED DESCRIPTION OF THE INVENTION

- 6 -

The term "knockout" refers to partial or complete reduction of the expression of at least a portion of a polypeptide encoded by an endogenous gene (such as OPG) of a single cell, selected cells, or all of the cells of a mammal. The mammal may be a "heterozygous knockout", wherein one allele of the endogenous gene has been disrupted. Alternatively, the mammal may be a "homozygous knockout" wherein both alleles of the endogenous gene have been disrupted.

10 The term "knockout construct" refers to a nucleotide sequence that is designed to decrease or suppress expression of a polypeptide encoded by an endogenous gene in one or more cells of a mammal. The nucleotide sequence used as the knockout construct is typically comprised of (1) DNA from some portion of the endogenous gene (one or more exon sequences, intron sequences, and/or promoter sequences) to be suppressed and (2) a marker sequence used to detect the presence of the knockout construct in the cell. The knockout construct is inserted into a cell containing the endogenous gene to be knocked out. The knockout construct can then integrate within one or both alleles of the endogenous OPG gene, and such integration of the OPG knockout construct can prevent or interrupt transcription of the full-length endogenous OPG gene. Integration of the OPG knockout construct into the cellular chromosomal DNA is typically accomplished via homologous recombination (i.e., regions of the OPG knockout construct that are homologous or complimentary to endogenous OPG DNA sequences can hybridize to each other when the knockout construct is inserted into the cell; these regions can then recombine so that the knockout construct is incorporated into the corresponding position of the endogenous DNA).

35 Typically, the knockout construct is inserted into an undifferentiated cell termed an embryonic stem

- 7 -

cell (ES cell). ES cells are usually derived from an embryo or blastocyst of the same species as the developing embryo into which it can be introduced, as discussed below.

5 The phrases "disruption of the gene", "gene disruption", "suppressing expression", and "gene suppression", refer to insertion of an OPG nucleotide sequence knockout construct into a homologous region of the coding region of the endogenous OPG gene (usually
10 containing one or more exons) and/or the promoter region of this gene so as to decrease or prevent expression of the full length OPG molecule in the cell. Insertion is usually accomplished by homologous recombination. By way of example, a nucleotide
15 sequence knockout construct can be prepared by inserting a nucleotide sequence comprising an antibiotic resistance gene into a portion of an isolated nucleotide sequence encoding OPG that is to be disrupted. When this knockout construct is then
20 inserted into an embryonic stem cell ("ES cell"), the construct can integrate into the genomic DNA of at least one OPG allele. Thus, many progeny of the cell will no longer express OPG at least in some cells, or will express it at a decreased level and/or in a
25 truncated form, as at least part of the endogenous coding region of OPG is now disrupted by the antibiotic resistance gene.

 The term "marker sequence" refers to a nucleotide sequence that is (1) used as part of a
30 larger nucleotide sequence construct (i.e., the "knockout construct") to disrupt the expression of OPG, and (2) used as a means to identify those cells that have incorporated the OPG knockout construct into the chromosomal DNA. The marker sequence may be any
35 sequence that serves these purposes, although typically it will be a sequence encoding a protein that confers a

- 8 -

detectable trait on the cell, such as an antibiotic resistance gene or an assayable enzyme not naturally found in the cell. The marker sequence will also typically contain either a homologous or heterologous promoter that regulates its expression.

The terms "rodent" and "rodents" refer to all members of the phylogenetic order *Rodentia* including any and all progeny of all future generations derived therefrom.

The term "murine" refers to any and all members of the family *Muridae*, including without limitation, rats and mice.

The term "progeny" refers to any and all future generations derived or descending from a particular mammal, i.e., a mammal containing one or more knockout constructs inserted into its genomic DNA, whether the mammal is heterozygous or homozygous for the knockout construct. Progeny of any successive generation are included herein such that the progeny, the F1, F2, F3, generations and so on indefinitely containing the knockout construct are included in this definition.

Included within the scope of this invention is a mammal in which one or both OPG alleles, as well as one or both alleles of another gene(s), have been knocked out. Such a mammal can be generated by repeating the procedures set forth herein for generating an OPG knockout mammal but using another gene, or by breeding two mammals, one with one or both alleles of OPG knocked out, and one with one or both alleles of a second gene knocked out, to each other, and screening for those offspring that have the double knockout genotype (whether a double heterozygous or a double homozygous knockout genotype, or a variation thereof).

- 9 -

Also included within the scope of this invention is a mammal in which 1) one or both OPG alleles, and optionally one or both alleles of another gene(s), have been knocked out, and 2) one or more transgenes (i.e., exogenous DNA sequence(s) encoding a polypeptide(s) that may or may not be naturally occurring in the mammal) have been inserted.

Knockout Technology

10

1. Isolation of the OPG Gene

An OPG knockout construct is typically prepared by isolating a portion of the genomic or cDNA OPG nucleotide sequence (usually encoding at least one exon and one intron), and inserting a marker sequence into the OPG sequence. The OPG gene or gene fragment to be used in preparing this construct may be obtained in a variety of ways. Generally, the OPG DNA molecule will be at least about 1 kilobase (kb) in length, and preferably will be 3-4 kb in length, thereby providing sufficient complementary sequence for recognition with chromosomal DNA (i.e., homologous recombination) when the knockout construct is introduced into the genomic DNA of the ES cell (discussed below).

A naturally occurring genomic OPG fragment or cDNA molecule to be used in preparing the knockout construct can be obtained using methods well known in the art such as those described by Sambrook et al. (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989)). Such methods include, for example, PCR amplification of a particular DNA sequence using oligonucleotide primers, or screening a genomic library prepared from cells or tissues that contain the OPG gene with a cDNA probe encoding at least a portion of

35

- 10 -

the same or a highly homologous OPG gene in order to obtain at least a portion of the OPG genomic sequence. Alternatively, if a cDNA sequence is to be used in a knockout construct, the cDNA may be obtained by

5 screening a cDNA library (preferably one prepared from tissues or that express OPG, where the tissues or cells are derived from the same or a similar species of mammal as that to be rendered the knockout mammal) with oligonucleotide probes, homologous cDNA probes, or

10 antibodies (where the library is cloned into an expression vector). If a promoter sequence is to be used in the knockout construct, synthetic DNA probes or primers can be designed for screening a genomic library or for amplification using PCR, respectively.

15 Where the DNA sequence of the endogenous OPG gene is known, a DNA fragment encoding the desired portion of such gene may be manufactured synthetically, using chemical synthesis methods such as those described by Engels et al., (Angew. Chem. Int. Ed. Engl., 28:716-734 ((1989))). These methods include

20 *inter alia*, the phosphotriester, phosphoramidite, and H-phosphonate methods of nucleic acid synthesis. Typically, the genomic DNA fragment to be prepared will be several hundred base pairs in length. Since the

25 chemical synthesis methods set forth herein can be used to make nucleic acid sequences of up to about 100 base pairs, the native genomic DNA can be synthesized in 100 bp fragments which can then be ligated together using standard DNA ligation methods.

30 The OPG genomic DNA fragment or OPG cDNA molecule prepared for use in the knockout construct must be generated in sufficient quantity for genetic manipulation. Amplification may be conducted by 1) placing the fragment into a suitable vector and

35 transforming bacterial or other cells that can rapidly amplify the vector, 2) by PCR amplification, 3) by

- 11 -

synthesis with a DNA synthesizer, or 4) by other suitable methods.

2. Preparation of an OPG Knockout Construct

5

The OPG genomic DNA fragment, cDNA molecule, or PCR fragment to be used in making the OPG knockout construct can be digested with one or more restriction enzymes selected to cut at a location(s) such that a
10 second DNA molecule encoding a marker gene can be inserted in the proper position within the OPG genomic DNA fragment, cDNA molecule, or PCR fragment to be used in the construct. The proper position for marker gene insertion is one that will serve to decrease or prevent
15 transcription and/or expression of the full length endogenous OPG gene. This position will depend on various factors such as the available restriction sites in the sequence to be cut, whether an exon sequence or a promoter sequence, or both is (are) to be
20 interrupted, and whether several isoforms of OPG exist in the mammal (due to alternative splicing) and only one such isoform is to be disrupted. Preferably, the enzyme(s) selected for cutting the OPG genomic DNA, cDNA molecule, or PCR fragment will generate a longer
25 arm and a shorter arm, where the shorter arm is at least about 300 base pairs (bp). In some cases, it will be desirable to actually delete a portion or even all of one or more introns or exons of this native genomic or cDNA molecule. In these cases, the OPG
30 genomic DNA, cDNA molecule, or PCR fragment can be cut with appropriate restriction endonucleases such that a fragment of the proper size and proper location can be removed.

The marker gene used in the knockout
35 construct can be any nucleic acid molecule that is detectable and/or assayable after it has been

- 12 -

incorporated into the genomic DNA of the ES cell, and ultimately the knockout mammal, however typically it is an antibiotic resistance gene or other gene whose expression or presence in the genome can easily be
5 detected. Preferably, the marker gene encodes a polypeptide that does not naturally occur in the mammal. The marker gene is usually operably linked to its own promoter or to another strong promoter such as the thymidine kinase (TK) promoter or the
10 phosphoglycerol kinase (PGK) promoter from any source that will be active or can easily be activated in the cell into which it is inserted; however, the marker gene need not have its own promoter attached, as it may be transcribed using the promoter of the gene to be
15 knocked out. In addition, the marker gene will normally have a polyA sequence attached to its 3' end; this sequence serves to terminate transcription of the marker gene. Preferred marker genes are any antibiotic resistance gene such as *neo* (the neomycin resistance
20 gene) and *beta-gal* (beta-galactosidase).

After the OPG genomic DNA fragment, cDNA molecule, or PCR fragment has been digested with the appropriate restriction enzyme(s), the marker gene molecule can be ligated with the native genomic DNA or
25 cDNA molecule using methods well known to the skilled artisan and described in Sambrook et al., supra. In some cases, it will be preferable to insert the marker sequence in the reverse or antisense orientation with respect to the OPG nucleic acid sequence; this reverse
30 insertion is preferred where the marker gene is operably linked to a particularly strong promoter.

The ends of the DNA molecules to be ligated must be compatible; this can be achieved by either cutting all fragments with those enzymes that generate
35 compatible ends, or by blunting the ends prior to ligation. Blunting can be done using methods well

- 13 -

known in the art, such as for example by the use of Klenow fragment (DNA polymerase I) to fill in sticky ends. After ligation, the ligated constructs can be screened by selective restriction endonuclease
5 digestion to determine which constructs contain the marker sequence in the desired orientation.

The ligated DNA knockout construct may be transfected directly into embryonic stem cells (discussed below), or it may first be placed into a
10 suitable vector for amplification prior to insertion. Preferred vectors are those that are rapidly amplified in bacterial cells such as the pBluescript II SK vector (Stratagene, San Diego, CA) or pGEM7 (Promega Corp.,
Madison, WI).

15

3. Transfection of Embryonic Stem Cells

The OPG knockout construct is typically transfected into stem cells derived from an embryo
20 (embryonic stem cells, or "ES cells") ES cells are undifferentiated cells that are capable of taking up extra-chromosomal DNA and incorporating it into their chromosomal DNA. Generally, the ES cells used to produce the knockout mammal will be of the same species
25 as the knockout mammal to be generated. Thus for example, mouse embryonic stem cells will usually be used for generation of knockout mice.

The embryonic stem cell line used is typically selected for its ability to integrate into
30 and become part of the germ line of a developing embryo so as to create germ line transmission of the knockout construct. Thus, any ES cell line that is believed to have this capability is suitable for use herein. Preferred ES cell lines for generating knockout mice
35 are murine cell lines D3 and E14 (American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD 20852-

- 14 -

1776 USA, catalog nos. CRL 1934 and CRL 1821, respectively), or RW4 (Genome Systems, Inc., 8620 Pennell Drive, St. Louis, Mi 63114 USA, catalog No. ESVJ-1182). The cells are cultured and prepared for
5 DNA insertion using methods well known to the skilled artisan such as those set forth by Robertson (in: Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, E.J. Robertson, ed. IRL Press, Washington, DC. (1987)), by Bradley et al. (Current Topics in
10 Devel. Biol., 20:357-371 (1986)) and by Hogan et al. (Manipulating the Mouse Embryo: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1986)).

Insertion (also termed "transfection") of the
15 knockout construct into the ES cells can be accomplished using a variety of methods well known in the art including for example, electroporation, microinjection, and calcium phosphate treatment (see Lovell-Badge, in Robertson, ed., supra). A preferred
20 method of insertion is electroporation.

The OPG knockout construct DNA molecules to be transfected into the cells can first be linearized if the knockout construct has previously been inserted into a circular vector. Linearization can be
25 accomplished by digesting the DNA with a suitable restriction endonuclease selected to cut only within the vector sequence and not within the knockout construct sequence. The isolated OPG knockout construct DNA can be added to the ES cells under
30 appropriate conditions for the insertion method chosen. Where more than one construct is to be introduced into the ES cells, the DNA molecules encoding each construct can be introduced simultaneously or sequentially. Optionally, homozygous OPG knockout ES cells may be
35 generated by adding excessive OPG knockout construct DNA to the cells, or by conducting successive rounds of

- 15 -

transfection in an attempt to achieve homologous recombination of the knockout construct on both endogenous OPG alleles.

If the ES cells are to be electroporated, the
5 ES cells and knockout construct DNA are exposed to an electric pulse using an electroporation machine and following the manufacturer's guidelines for use. After electroporation, the cells are typically allowed to recover under suitable incubation conditions. The
10 cells are then screened for the presence of the knockout construct.

Screening the ES cells can be accomplished using a variety of methods, but typically, one screens for the presence of the marker sequence portion of the
15 knockout construct. Where the marker gene is an antibiotic resistance gene, the cells can be cultured in the presence of an otherwise lethal concentration of antibiotic. Those cells that survive have presumably integrated the knockout construct. If the marker gene
20 is other than an antibiotic resistance gene, a Southern blot of the ES cell genomic DNA can be probed with a sequence of DNA designed to hybridize only to the marker sequence. If the marker gene is a gene that encodes an enzyme whose activity can be detected (e.g.,
25 beta-galactosidase), the enzyme substrate can be added to the cells under suitable conditions, and the enzymatic activity of the marker gene can be analyzed.

The knockout construct may integrate into several locations in the ES cell genome, and may
30 integrate into a different location in each cell's genome, due to the occurrence of random insertion events; the desired location of insertion is within the OPG endogenous gene sequence. Typically, less than about 1-10 percent of the ES cells that take up the
35 knockout construct will actually integrate the knockout construct in the desired location. To identify those

- 16 -

cells with proper integration of the knockout construct, chromosomal DNA can be extracted from the cells using standard methods such as those described by Sambrook et al., supra. This DNA can then be probed on
5 a Southern blot with a probe or probes designed to hybridize to the knockout construct DNA digested with (a) particular restriction enzyme(s). Alternatively, or additionally, a specific genomic DNA sequence can be amplified by PCR with probes specifically designed to
10 amplify that DNA sequence such that only those cells containing the knockout construct in the proper position will generate DNA fragments of the proper size.

15 4. ES Cell Incorporation/Implantation of Embryos

After suitable ES cells containing the knockout construct in the proper location have been
20 identified, the cells can be incorporated into an embryo. Incorporation may be accomplished in a variety of ways. A preferred method of incorporation of ES cells is by microinjection into an embryo that is at the blastocyst stage of development. For
25 microinjection, about 10-30 cells are collected into a micropipet and injected into a blastocyst to integrate the ES cell into the developing blastocyst.

The suitable stage of development for the blastocyst is species dependent, however for mice it is
30 about 3.5 days. The blastocysts can be obtained by perfusing the uterus of pregnant females. Suitable methods for accomplishing this are known to the skilled artisan, and are set forth for example by Bradley (in Robertson, ed., supra).

35 While any blastocyst of the right age/stage of development is suitable for use, preferred

- 17 -

blastocysts are male and have genes coding for a coat color or other phenotypic marker that is different from the coat color or other phenotypic marker encoded by the ES cell genes. In this way, the offspring can be
5 screened easily for the presence of the knockout construct by looking for mosaic coat color or other phenotypic marker (indicating that the ES cell was incorporated into the developing embryo). Thus, for example, if the ES cell line carries the genes for
10 white fur, the embryo selected will preferably carry genes for black or brown fur.

An alternate method of preparing an embryo containing ES cells that possess the knockout construct is to generate "aggregation chimeras". A morula of the
15 proper developmental stage (about 2 1/2 days old for mice) is isolated. The *zona pellucida* can be removed by treating the morula with a solution of mild acid for about 30 seconds, thereby exposing the "clump" of cells that comprise the morula. Certain types of ES cells
20 such as the R1 cell line for mice can then be co-cultured with the morula cells, forming an aggregation chimera embryo of morula and ES cells.

A refinement of the aggregation chimera embryo method can be used to generate an embryo
25 comprised of essentially only those ES cells containing the knockout construct. In this technique, a very early stage zygote (e.g., a two-cell stage zygote for mice) is given a mild electric shock. This shock serves to fuse the nuclei of the cells in the zygote
30 thereby generating a single nucleus that has two-fold (or more) the DNA of a naturally occurring zygote of the same developmental stage. These zygotic cells are excluded from the developing embryo proper, and contribute only to forming accessory embryonic
35 structures such as the extra-embryonic membrane. Therefore, when ES cells are co-cultured with the

- 18 -

zygotic cells, the developing embryo is comprised exclusively of ES cells.

After the ES cells have been incorporated, the aggregation chimera or transfected embryo can be
5 implanted into the uterus of a pseudopregnant foster mother. While any foster mother may be used, preferred foster mothers are typically selected for their ability to breed and reproduce well, and for their ability to care for their young. Such foster mothers are typically
10 prepared by mating with vasectomized males of the same species. The pseudopregnant stage of the foster mother is important for successful implantation, and it is species dependent. For mice, this stage is about 2-3 days pseudopregnant.

15

5. Screening for the OPG Knockout Gene

Offspring that are born to the foster mother may be screened initially for mosaic coat color or
20 other phenotype marker where the phenotype selection strategy (such as coat color, as described above) has been employed. In addition, or as an alternative, chromosomal DNA obtained from tail tissue of the offspring may be screened for the presence of the
25 knockout construct using Southern blots and/or PCR as described above. The offspring that are positive for the OPG knockout construct will typically be heterozygous, although some homozygous knockouts may exist, and can typically be detected by visually
30 quantifying the amount of probe that hybridizes to the Southern blots.

If homozygous knockout mammals are desired, they can be prepared by crossing those heterozygous offspring believed to carry the knockout construct in
35 their germ line to each other; such crosses may generate homozygous knockout animals. If it is unclear

- 19 -

whether the offspring will have germ line transmission, they can be crossed with a parental or other strain and the offspring screened for heterozygosity. Homozygotes may be identified by Southern blotting of equivalent
5 amounts of genomic DNA from mammals that are the product of this cross, as well as mammals of the same species that are known heterozygotes, and wild-type mammals. Probes to screen the Southern blots for the presence of the knockout construct in the genomic DNA
10 can be designed as set forth above.

Other means of identifying and characterizing the knockout offspring are also available. For example, Northern blots can be used to probe mRNA obtained from various tissues of the offspring for the
15 presence or absence of transcripts encoding either the gene knocked out, the marker gene, or both. In addition, Western blots can be used to assess the level of expression of the gene knocked out in various tissues of these offspring by probing the Western blot
20 with an antibody against the protein encoded by the gene knocked out, or an antibody against the marker gene product, where this gene is expressed. Finally, in situ analysis (such as fixing the cells and labeling with antibody) and/or FACS (fluorescence activated cell
25 sorting) analysis of various cells from the offspring can be conducted using suitable antibodies to look for the presence or absence of the knockout construct gene product.

Both the heterozygous and homozygous OPG
30 knockout mammals of this invention will have a variety of uses, since OPG has been implicated in regulation of differentiation and activation of osteoclasts. One such use will be to use the mammal as an in vivo screening system for drugs that affect bone resorption.
35 It is known that osteoclast numbers increase in certain bone diseases, as well as in response to certain

- 20 -

cytokines or hormones (i.e., interleukin-1 (IL-1) or parathyroid hormone (PTH)) that stimulate bone resorption. In addition, certain diseases such as osteoporosis generally result in imbalances between
5 bone resorption and bone formation. As such, the claimed mammals may be used to screen for drugs useful for altering osteoclast numbers and/or activity, i.e., drugs that either enhance or inhibit these activities, depending on the disease under study.

10 Screening for such useful drugs typically involves administering the candidate drug over a range of doses to the mammal, and assaying at various time points for the bone density effect(s) of the drug on the disorder being evaluated. Such assays would
15 include, for example, looking for increased or decreased osteoclast numbers, increased or decreased bone resorption, increased or decreased bone production and/or density, increased or decreased levels and/or activity of chemical messengers such as interleukins,
20 and/or increased or decreased levels of expression of a particular gene(s) involved in the modulation of bone density.

For example, patients with osteoporosis often experience bone fractures. It would be desirable to
25 block osteoclast-mediated bone resorption in such individuals by administering to the patient a therapeutic agent capable of producing such an effect. A mammal of the present invention could be used to screen a variety of compounds, either alone or in
30 combination, to determine whether partial or total inhibition of osteoclast-mediated bone resorption results from the use of such drug.

The same strategy could be applied to find compounds that would be useful in suppressing bone
35 resorption in patients with other diseases of bone loss, such as hypercalcemia of malignancy or in

- 21 -

patients with disorders of bone remodeling, such as Paget's disease.

In addition, a mammal of the present invention can be useful for evaluating the development
5 and function of various components of the skeletal system, and for studying the effects of particular gene mutations. For example, in a mammal not expressing OPG, one can analyze the effect of the lack of such expression on other components of the skeletal system.

10 Other uses of the claimed mammals and compounds will be readily apparent to one of skill in the art.

The invention will be more fully understood
15 by reference to the following examples. These examples are not to be construed in any way as limiting the scope of this invention.

EXAMPLES

20

Example 1: Preparation of an OPG Knockout Construct

To obtain murine OPG genomic DNA clones, a
129 SVJ Mouse genomic library in Lambda Fix II Vector
25 (Stratagene, Inc., 11011 North Torrey Pines Road, La Jolla, CA 92037, catalog No. 946309) was screened with a radiolabeled DNA fragment corresponding to nucleotides 90-1296 of the murine OPG cDNA (Genbank accession No.
30 U94331). Eleven clones were obtained when the library was screened at a stringency of about 55°C in about 40 mM sodium phosphate, pH 7.4. These clones were further subdivided by screening with cDNA fragments from the 5' and 3' ends of the coding sequence. The 5' clones were
35 analyzed by Southern blot analysis following digestion with EcoRI.

- 22 -

Recovery of the cloned sequences and plasmid amplification was conducted using LambdaSorb Phage Adsorbent™ (Promega, Inc., 2800 Woods Hollow Road, Madison, WI 53711-5399 USA, catalog # A7051) according to the manufacturer's protocol. One clone (fragment 1) was then prepared as a *EcoRI/EcoRI* fragment and was approximately 1.7 kb. A second clone was prepared as a *EcoRI/EcoRI* fragment (fragment 2) and was about 5.5 kb in length. Fragment 1 contained a portion of intron 1 and most of exon 2 (see Figure 1) and fragment 2 contained the 3' portion of exon 2, intron 2, exon 3, and most of intron 3 (see Figure 1). A third clone prepared as a 1.1 kb *XmnI/XmnI* fragment (fragment 3) was derived as a subfragment of fragment 1 (see Figure 1). Fragments 2 and 3, along with a neo cassette containing a PGK (phosphoglycerate kinase) promoter derived from the pKJ-1 vector (Tybutewicz et al., Cell, 65:1153-1163 (1991); Adra et al., Gene, 60:65-74 (1987)) and a TK cassette (thymidine kinase gene with a PGK promoter; Tybutewicz et al., supra) were directionally cloned, using standard ligation techniques, into the vector pBluescript (Stratagene, La Jolla, CA) to generate a knockout construct containing, from 5' to 3', OPG genomic fragment 3, the neo cassette, OPG genomic fragment 2, and the TK (see Figure 1). Both the TK cassette and the neo cassette were ligated in the antisense direction. To confirm proper ligation, the cloning junctions were sequenced.

This vector, containing all components in the proper orientation, was linearized with *NotI* and then electroporated into RW4 embryonic stem cells as follows: about 25 µg of linearized DNA was added to about 9×10^6 ES cells in a volume of about 900 µl of PBS. The cells were pulsed at about 0.23 kilovolts and about 500 µF, and each vial of cells was then plated onto two 60 mm cell culture plates with feeder cells.

- 23 -

The plates contained about 10 ml of DMEM medium (Gibco/BRL, Grand Island, NY), 15 percent fetal calf serum (Gibco/BRL, Grand Island, NY or equivalent from Hyclone Labs, Logan, UT), and leukemia inhibitory factor (Fung-Leung et al. Cell, 65:443-449 (1991)), 10^{-5} M B-mercaptoethanol, 2mM L-glutamine, and 1mM sodium pyruvate. After two days in culture, the cells were selected in the presence of gangcyclovir and G418 to enrich for cells which had undergone homologous recombination (Cappecchi, Science, 244:1288 [1989]; Shahinian et al., Science, 261:609 (1993)); surviving cells were collected, and cultured further in medium containing G418 but not gangcyclovir. To confirm homologous recombination, the cells that grew in the presence of G418 were then screened by Southern blot analysis using genomic DNA prepared from the cells and cut with *EcoRI* (see Figure 2).

Samples of RW4 cells that have undergone homologous recombination to incorporate the OPG knockout construct in their genomic DNA have been deposited with the American Type Culture Collection ("ATCC", 12301 Parklawn Drive, Rockville, MD 20852, USA) as accession number CRL-12418, with a deposit date of October 9, 1997.

25

Example 2: Preparation of OPG Knockout Mice

The RW4 cells containing the OPG knockout construct were inserted into fertilized embryos (blastocysts) that were approximately 3.5 days old, which were obtained from C57BL/6 mice by perfusing the uterus of female C57BL/6 mice that had been mated with male mice. Insertion was accomplished by microinjecting about 15-30 cells into each blastocyst. The embryos were then implanted into CD1 pseudo pregnant female mice at day 2.5 post coitum for

- 24 -

gestation. The chimeric male offspring of these foster mothers were screened for agouti coat color and were crossed with female C57BL/6 or swiss black females. Germline transmission of the knockout construct was
5 determined by coat color of the F₁ pups; agouti pups were identified as heterozygous OPG knockouts. These F₁ pups were crossed with each other to generate F₂ homozygotes. The homozygotes (OPG^{-/-}) were identified and distinguished from heterozygotes (OPG^{+/-}) and
10 wildtype (OPG^{+/+}) mice by Southern blot analysis of genomic DNA cut with *Pst*I and probed with a *Eco*RI/*Xmn*I OPG specific probe which was used to confirm homologous recombination (see Figure 3).

15 Example 3: Characterization of OPG Knockout Mice

The following procedures were used for all analyses described below in which qualitative and/or quantitative phenotypic analysis of bone and other
20 tissues of OPG knockout and control mice was performed. At 8-10 weeks of age, 3 homozygous OPG knockout mice (OPG^{-/-}), 5 heterozygous OPG knockout mice (OPG^{+/-}) and 4 control mice (OPG^{+/+}) were necropsied (see Table 1). Radiography was performed prior to the gross
25 dissection. Serum from the mice was analyzed for clinical chemistries and full hematology. Total body and major organs were weighed and fixed in formalin. Tibias for pQCT measurements were fixed in 70% ETOH. The bone density in the proximal tibial metaphysis and
30 tibial cortical shaft of wild type, heterozygous, and OPG^{-/-} mice was determined by quantitative CT scanning (pQCT) (Stratec, Germany). Two standard slices of bone, 0.5mm in thickness 1.5mm from the proximal end and a single 0.5mm slice 4mm from the proximal end of
35 the tibia were used to determine the trabecular bone density in the metaphysis and the mineral content and

- 25 -

density of the cortical shaft respectively. Other bone tissue was decalcified using a formic acid solution, and all sections were stained with H & E. Enzyme histochemistry was performed to determine the
5 expression of expression of tartarate resistant acidic phosphatase (TRAP). Seven additional OPG^{-/-} mice between 8 and 16 weeks of age were bled for serum chemistries. These mice were designated 1-51, 1-56, 1-68, 1-74, 1-83, 4-78 and 4-79.

10

- 26 -

TABLE 1
Knockout Mice Undergoing Necropsy

OPG (+/+)	OPG (+/-)	OPG (-/-)
1-34	1-28	1-27
1-37	1-29	1-26 ♦
1-45	1-35	1-38 ▼
1-25	1-36	
	1-46	

- 5 ♦ OPG^{-/-} Mouse 1-26 was the runt of the litter, about half the size of a normal mouse. It became moribund and died shortly before the scheduled sacrifice, it displayed the signs of respiratory insufficiency shortly before dying. Blood for hematology and serum
- 10 chemistries was drawn immediately after death by cardiac puncture and a regular necropsy was performed.
- ▼ OPG^{-/-} Mouse 1-38 was placed in one cage with OPG^{-/-} mouse 1-27 in preparation for the procedures and died within the last 1 hour prior to sacrifice, no blood
- 15 could be collected for testing. The rest of the autopsy was performed as usual and organs submitted for histology.

Pathological evaluation of 8-10 week old OPG

20 wild type, heterozygous knockout and homozygous knockout mice indicated that all three homozygous (OPG^{-/-}) knockout mice have severe osteoporosis. The OPG^{-/-} mice were x-rayed adjacent to wild type and/or heterozygous mice using the same x-ray film, to allow

25 direct comparison of bone density and structure (see Figure 4a). The three OPG^{-/-} mice varied markedly in size with 27 and 38 being of similar size to wild type mice and 26 being profoundly runted. The thoracic vertebrae of mouse 38 were clearly displaced indicating

30 spinal fracture as the cause of death.

- 27 -

There were several consistent differences between the radiological appearance of the bones in the knockout mice compared to those in wild type and heterozygote mice. The most clearly different region
5 was the distal femur (see Figure 4b). In the distal femoral metaphysis there was a marked reduction in density that was particularly severe in 38 and 26 and less severe in 27. In particular the clear radiodense outlining of the growth plate seen in wild type and
10 heterozygous mice was absent in all knockout mice. The cortical bone of the femur appeared thin in 38 and 26 and in all knockout mice the radiodensity of the cortical bone was decreased. There was also an apparent flattening of the normally rounded distal end
15 of the femur possibly indicating partial collapse or compression of the distal femoral epiphysis. In the proximal end of the tibia there was a loss of a clearly defined growth plate. In the vertebra there was also a reduction in bone density relative to wild type mice
20 with a reduction greatest in 26 and 38 and least in 27.

Histologic morphology of OPG knockout mice was also assessed. The lumbar vertebrae and proximal metaphyseal region of the humerus were profoundly osteoporotic with almost complete absence of trabeculae
25 (see Figure 5A, B, C, D). The cortical shafts of the humerus in these bones showed increased cortical porosity with the presence of very active remodeling of the cortical bone as evidenced by plentiful osteoclasts and osteoblasts (Figure 5E, F). Cortical bone in wild
30 type mice had few cavities or vascular channels and showed little evidence of remodeling (Figure 5E) whereas in the OPG^{-/-} mice extensive cortical bone porosity was present (Figure 5F). In the proximal epiphysis of the OPG^{-/-} mice there was evidence of
35 resorption of the subchondral bone and collapse of the

- 28 -

joint surface with increased remodeling of the trabecular bone (Figure 5B).

The trabecular bone density was markedly reduced in the metaphyseal region ($268.5 \pm 0.16 \text{ mg/cm}^3$ versus $443.8 \pm 27 \text{ mg/cm}^3$ in the heterozygotes and $473.4 \pm 30 \text{ mg/cm}^3$ in the wild type group). The bone mineral content (0.526 mg/cm^3 versus $0.9 \pm 0.11 \text{ mg/cm}^3$ in the heterozygotes and $0.86 \pm 0.2 \text{ mg/cm}^3$ in the wild type), and cortical thickness were significantly reduced (to $0.23 \pm 0.03 \text{ mm}$ from $0.3 \pm 0.04 \text{ mm}$ in the wild type and $0.32 \pm 0.03 \text{ mm}$ in the heterozygote group) and cortical density was markedly but not statistically significantly reduced in the tibial cortical shaft.

Histomorphometry of the vertebrae and humerus revealed that the trabecular bone volume in the proximal metaphysis of the humerus is significantly reduced ($6.58 \pm 1.9 \%$ versus $21.66 \pm 8.6 \%$ in the wild type group), and the number of osteoclasts per mm of trabecular bone perimeter was significantly increased (4.88 ± 1.19 versus 3.2 ± 0.25 in the wild type group). In the vertebra similar changes in the trabecular bone volume were recorded, however osteoclast numbers were similar in the $\text{OPG}^{-/-}$ and wild type mice (Figure 5G and H).

No hematology parameters were different between the $\text{OPG}^{-/-}$ and $\text{OPG}^{-/-}$ groups. $\text{OPG}^{-/-}$ mouse 27 was no different from the previous groups, runt #26 had elevated hematocrit, white blood cell count, white blood cell, red blood cell, lymphocyte, monocyte and eosinophil counts due to terminal hemoconcentration. Blood was not available for analysis from #38.

Most chemistry values were normal and similar throughout the groups. Runt #26 had elevated serum calcium and serum cholesterol levels and severely decreased serum glucose. However, all $\text{OPG}^{-/-}$ mice, including the seven examined on the additional bleed

- 29 -

had elevated serum alkaline phosphatase (ALP) levels. On pooled analysis of the blood chemistry data of the sacrificed and the additionally bled OPG knockouts, the OPG^{-/-} mice had ALP values of 376.3±36.6 IU/l versus
5 115.7±55 IU/l in the OPG^{+/-} and 116.4±36.6 IU/l in the OPG^{+/-} mice (p<0.001).

* * *

10 While the present invention has been described in terms of the preferred embodiments, it is understood that variations and modifications will occur to those skilled in the art. Therefore, it is intended that the appended claims cover all such equivalent
15 variations which come within the scope of the invention as claimed.

- 30 -

WHAT IS CLAIMED IS:

1. A non-human mammal comprising the gene
5 encoding OPG wherein one allele of the gene has been
disrupted.
2. A non-human mammal comprising the gene
encoding OPG wherein both alleles of the gene have been
10 disrupted.
3. A non-human mammal comprising a disrupted
OPG mutation, wherein the disruption results in a null
mutation of the gene encoding OPG.
15
4. The non-human mammal of any of Claims 1,
2 and 3 which is a rodent.
5. The non-human mammal of Claim 4 which is
20 a mouse.
6. The non-human mammal of any of Claims 1,
2 and 3 characterized by having decreased bone density
or increased bone resorption.
25
7. A nucleic acid molecule comprising an OPG
knockout construct.
8. A vector comprising the nucleic acid of
30 claim 7.
9. A murine RW4 embryonic stem cell line
comprising the nucleic acid molecule of claim 8.

- 31 -

10. A method of screening compounds that modulate bone resorption comprising introducing the compounds into the non-human mammal of any of Claims 1,
5 2 and 3 and determining the increase or decrease in bone resorption.

1 / 7




FIG. 1A




FIG. 1B





FIG. 1C


2 / 7

FIG. 2




3 / 7

FIG. 3



4 / 7

FIG.4A



1-25 +/+

FIG.4B



1-29 +/-

FIG.4C



1-46 +/-

FIG.4D



1-26 -/-

FIG.4E



1-27 -/-


FIG.4F



1-38 -/-


5 / 7

FIG.4G




1-26 -/-

FIG.4H



1-27 -/-

FIG.4I



1-38 -/-

FIG.4J



1-37 +/-

FIG.4K



1-45 +/-

FIG.4L



1-46 +/-

6 / 7

FIG.5A



FIG.5B



FIG.5C



FIG.5D

818

FIG.5E



FIG.5F





FIG.5G

FIG.5H

INTERNATIONAL SEARCH REPORT

Int. l. Application No

PCT/US 98/19852

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/00 C07K14/705

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 784 093 A (AMGEN INC) 16 July 1997 see the whole document	1-10
Y	<p>SIMONET W S ET AL: "Osteoprotegerin: a novel secreted protein involved in the regulation of bone density 'see comments!'"</p> <p>CELL, (1997 APR 18) 89 (2) 309-19. JOURNAL CODE: CQ4. ISSN: 0092-8674., XP002090117 cited in the application</p> <p>see the whole document</p> <p style="text-align: center;">-/--</p>	1-10

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

19 January 1999

Date of mailing of the international search report

01/02/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3018

Authorized officer

Hardon, E

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/19852

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	KARAPLIS, ANDREW C.: "Gene targeting." , BILEZIKIAN, J. P. 'EDITOR!;RAISZ, L. G. 'EDITOR!; RODAN, G. A. 'EDITOR!. (1996) PP. 1189-1201. PRINCIPLES OF BONE BIOLOGY. PUBLISHER: ACADEMIC PRESS, INC. 1250 SIXTH AVE., SAN DIEGO, CALIFORNIA 92101, USA. ISBN: 0-12-098650-7. XP002090123 see page 1190, column 2, line 11-16 see page 1198, column 2, line 38 - page 1200, column 1, line 33	1-10
Y	GALLI-TALIADOROS L A ET AL: "Gene knock-out technology: a methodological overview for the interested novice" JOURNAL OF IMMUNOLOGICAL METHODS, vol: 181, no. 1, 12 April 1995, page 1-15 XP004021051 see the whole document	1-10
P,X	BUWAY N ET AL: "osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification." GENES AND DEVELOPMENT, (1998 MAY 1) 12 (9) 1260-8. JOURNAL CODE: FN3. ISSN: 0890-9369., XP002090118 see the whole document	1-10
P,X	MIZUNO A ET AL: "Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1998 JUN 29) 247 (3) 610-5. JOURNAL CODE: 9Y8. ISSN: 0006-291X., XP002090119 see the whole document	1-10
P,A	EP 0 816 380 A (SNOW BRAND MILK PROD CO LTD) 7 January 1998 see the whole document	1-10

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Patent Application No

PCT/US 98/19852

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0784093 A	16-07-1997	AU 1468697 A	17-07-1997
		CA 2210467 A	03-07-1997
		CN 1182452 A	20-05-1998
		DE 19654610 A	26-06-1997
		EP 0870023 A	14-10-1998
		FR 2742767 A	27-06-1997
		GB 2312899 A	12-11-1997
		HU 9801122 A	28-08-1998
		NO 973699 A	21-10-1997
		PL 321938 A	05-01-1998
		WO 9723614 A	03-07-1997
EP 0816380 A	07-01-1998	AU 4677396 A	11-09-1996
		FI 973402 A	17-10-1997
		NO 973801 A	20-10-1997
		CA 2213469 A	29-08-1996
		CN 1175956 A	11-03-1998
		WO 9626217 A	29-08-1996